Latest Headlines

Latest Headlines

Wave and Voyager keep the IPO train rolling, raising $172M in Wall Street debuts

As Wall Street vacillates on the whole biotech sector, each week becomes an unwitting referendum on just how long the IPO window for drug developers might stay open. Voyager Therapeutics and Wave Life Sciences, raising a combined $172 million this week, demonstrated that biotech's years-long boom on the public markets is not quite through.

Sanofi unveils its work on improving flu vaccines

This week at the World Vaccines Congress in Spain, Sanofi Pasteur announced that in collaboration with the University of Georgia it has developed a candidate flu vaccine through genetic sequencing of many flu viruses. The vaccine, dubbed Cobra, is designed to protect against multiple strains over several years using common sequences the strains share.

Stanford engineers develop touch-free ultrasound device for tumor detection

As scientists search for lighter, low-cost alternatives to traditional imaging tools such as MRI or CT scans, engineers at Stanford University are developing a device that uses microwaves and ultrasound to pinpoint targets without touch, potentially improving tumor detection.

Ex-Lumena gang pilots new course at Amplyx with antifungal R&D, $40.5M

Some of the old San Diego gang that brought you Lumena--bought out by Shire last year--have moved into top positions at Amplyx Pharmaceuticals as the biotech heads in a new direction, pointing a recently in-licensed antifungal product toward the clinic with $40.5 million from a high-profile group of venture players.

GE Healthcare, Shine advance tech to create imaging radioisotope without weapons-grade uranium

The race is on to develop U.S. sources for a material necessary to create the most widely used radioisotope in medical diagnostic imaging. Now GE Healthcare and startup Shine Technologies have disclosed that they have successfully used GE's existing tech to create the common medical radioisotope technetium-99m (Tc‑99m) from molybdenum-99 (Mo-99) produced by Shine.

Genentech, Exelixis win FDA OK to market cobimetinib combo for skin cancer

Just weeks after announcing a fresh batch of promising Phase III data, the FDA has handed Genentech and its biotech partner Exelixis an approval to market cobimetinib in combination with Zelboraf among a genetically defined group of melanoma patients.

UCLA researchers use drug delivery to improve treatment of bioterrorism agent

Researchers at UCLA's California NanoSystems Institute have developed a nanoparticle delivery system that improves an antibiotic's ability to combat the bacteria  Francisella tularensis.

Injectable HIV regimen being developed by J&J and ViiV Healthcare shows promise in trials

Johnson & Johnson's Janssen announced that a Phase IIb study of a combination regimen of two investigational long-acting injectable HIV drugs found that the therapy performed similarly to a regimen consisting of three oral medications.

Scientists make strides toward full-body PET scanner with $15.5M in tow

Researchers are developing the world's first total-body positron emission tomography (PET) scanning device to improve disease diagnosis and treatment.

Sanofi's back-to-growth strategy fails to impress analysts

If Sanofi CEO Olivier Brandicourt wanted to win over analysts with Friday's pronouncements about the company's future, he must be disappointed now. A slew of investment firms cut their price targets and several downgraded the shares, as the French drugmaker's strategy for future growth was outweighed by warnings about stagnant earnings for the next few years.